Is Cemiplimab an immunotherapy drug or a targeted drug?

From the perspective of pharmacological mechanism and internationally accepted classification, Cemiplimab is an immunotherapy drug rather than a "targeted drug" in the traditional sense. It is a fully humanized anti-PD-1 monoclonal antibody that blocks the binding of the PD-1 receptor on the surface of T cells to its ligand (PD-L1/PD-L2), thereby releasing the "brake" of the tumor microenvironment on T cells, thereby restoring and amplifying the body's immune response to tumors.

In contrast, targeted therapy usually directly targets abnormal signaling pathways or specific driver mutations within tumor cells, such as small molecule inhibitors of certain receptor tyrosine kinases or downstream pathways. It is characterized by "precisely attacking specific molecular targets" and more directly inhibiting tumor cells carrying corresponding biomarkers. Immunotherapy and targeted therapy are often used interchangeably in clinical contexts, but the core difference between them is that the former "activates the immune system to indirectly eliminate tumors", while the latter "directly inhibits key tumor signals."

Based on this,Cemiplimab is more accurately classified as an "immune checkpoint inhibitor (PD-1 inhibitor)." At the application level, the benefits of immunotherapy vary among individuals. The time of onset of imaging remission, the persistence of remission, and the spectrum of immune-related adverse reactions (such as rash, endocrine abnormalities, immune pneumonitis, or hepatitis, etc.) are all related to the immune ecology and tumor characteristics of the patient. Therefore, in clinical practice, full monitoring and management are usually carried out based on the condition, comorbidities, and previous treatments.

In recent years,PD-1 monoclonal antibodies have been proven to form complementary strategies with chemotherapy, radiotherapy or anti-angiogenic treatment in multiple tumor areas, reflecting the importance of the concept of "immune remodeling" in oncology. For readers who are searching for "cimilumab immunotherapy or targeted drugs", clarifying its immune attributes will help to correctly understand the efficacy mechanism, expected management and adverse reaction monitoring path.

Reference materials:https://www.libtayohcp.com/